Studies on synthetic PPAR antagonist showed that blocking or reducing the activity of PPARγ can reduce HFD-induced adipocyte hypertrophy and insulin resistance by reducing the size of adipocytes and decreasing the secretion of TNF-α and leptin (Abbas et al., 2013; Rieusset et al., 2002). The gene discussed is TNF; the disease is Insulin resistance.